BioSpace News Archive

DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced today that the first patient has been enrolled in its Phase 1b study combining temozolomide and eflornithine in patients newly diagnosed with glioblastoma.

Capricor Therapeutics today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately.

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) will be presenting at the Emerging Growth Conference on September 6, 2023 (https://emerginggrowth.com/conference/).

Phononic, a global leader in sustainable solid state cooling, today announced a strategic supply agreement to provide thermoelectric cooling devices and related design and engineering services to Luminar, a global automotive technology company ushering in a new era of vehicle safety and autonomy.

Caldera Medical announced today that it has completed its acquisition of Atlantic Therapeutics, an Ireland based provider of non-invasive pelvic floor strengthening and nerve stimulating solutions for women. a

Cassava Sciences, Inc., a biotechnology company committed to the treatment of Alzheimer’s disease dementia, announced that it has been invited to present at the following investor conferences.

Cardio Diagnostics Holdings, Inc, a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced its AI-driven Epi+Gen CHD and PrecisionCHD tests will be leveraged in a research study led by Dr. Vishal Gupta, a cardiologist and the head of the Heart Attack Prevention Clinic at Ascension Borgess.

Biological Dynamics, Inc. and the Pancreatic Cancer Early Detection (PRECEDE) Consortium have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.

JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers